% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jaramillo:124287,
      author       = {S. Jaramillo and A. Benner$^*$ and J. Krauter and H. Martin
                      and T. Kindler and M. Bentz and H. R. Salih and G. Held and
                      C.-H. Köhne and K. Götze and M. Lübbert and A. Kündgen
                      and P. Brossart and M. Wattad and H. Salwender and B.
                      Hertenstein and D. Nachbaur and G. Wulf and H.-A. Horst and
                      H. Kirchen and W. Fiedler and A. Raghavachar and G. Russ and
                      S. Kremers and E. Koller and V. Runde and G. Heil and D.
                      Weber and G. Göhring and K. Döhner and A. Ganser and H.
                      Döhner and R. Schlenk$^*$},
      title        = {{C}ondensed versus standard schedule of high-dose
                      cytarabine consolidation therapy with pegfilgrastim growth
                      factor support in acute myeloid leukemia.},
      journal      = {Blood cancer journal},
      volume       = {7},
      number       = {5},
      issn         = {2044-5385},
      address      = {London [u.a.]},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2017-01183},
      pages        = {e564 -},
      year         = {2017},
      abstract     = {The aim of this cohort study was to compare a condensed
                      schedule of consolidation therapy with high-dose cytarabine
                      on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given
                      on days 1, 3 and 5 (HDAC-135) as well as to evaluate the
                      prophylactic use of pegfilgrastim after chemotherapy in
                      younger patients with acute myeloid leukemia in first
                      complete remission. One hundred and seventy-six patients
                      were treated with HDAC-135 and 392 patients with HDAC-123
                      with prophylactic pegfilgrastim at days 10 and 8,
                      respectively, in the AMLSG 07-04 and the German AML
                      Intergroup protocol. Time from start to chemotherapy until
                      hematologic recovery with white blood cells >1.0 G/l and
                      neutrophils >0.5 G/l was in median 4 days shorter in
                      patients receiving HDAC-123 compared with HDAC-135
                      (P<0.0001, each), and further reduced by 2 days (P<0.0001)
                      by pegfilgrastim. Rates of infections were reduced by
                      HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in
                      hospital and platelet transfusions were significantly
                      reduced by HDAC-123 compared with HDAC-135. Survival was
                      neither affected by HDAC-123 versus HDAC-135 nor by
                      pegfilgrastim. In conclusion, consolidation therapy with
                      HDAC-123 leads to faster hematologic recovery and less
                      infections, platelet transfusions as well as days in
                      hospital without affecting survival.},
      cin          = {C060 / G040},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)G040-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28548643},
      doi          = {10.1038/bcj.2017.45},
      url          = {https://inrepo02.dkfz.de/record/124287},
}